We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Astrazeneca Plc | LSE:AZN | London | Ordinary Share | GB0009895292 | ORD SHS $0.25 |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| -282.00 | -2.36% | 11,682.00 | 11,680.00 | 11,682.00 | 11,908.00 | 11,682.00 | 11,844.00 | 717,342 | 16:16:35 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Pharmaceutical Preparations | 54.07B | 7.04B | 4.5371 | 25.82 | 185.51B |
From Feb 2020 to Feb 2025
By Denise Roland
AstraZeneca PLC was boosted by a one-off tax windfall in the third quarter, helping offset heavy investment into the drugs it hopes will fuel strong growth.
The drugs giant posted a net profit of $1 billion for the three months to Sept. 30, 32% higher than in the same period a year earlier, while revenue dipped 4% to $5.7 billion. Analysts had expected net income of $731 million and revenue of $5.87 billion.
Cambridge, England-based Astra said profit was lifted by a $453 million payment relating to agreements between the Canadian tax authority and those of the U.K. and Sweden.
Core operating profit, a measure that strips out certain one-time gains and losses, declined 2% to $1.7 billion.
Write to Denise Roland at denise.roland@wsj.com
(END) Dow Jones Newswires
November 10, 2016 02:46 ET (07:46 GMT)
Copyright (c) 2016 Dow Jones & Company, Inc.
1 Year Astrazeneca Chart |
1 Month Astrazeneca Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
